Site Search
Professionals 126 results
Capabilities 36 results
Industry
Winston has been a major player in the life sciences industry for decades. We represent market-leading clients across this broad sector, including companies involved in pharmaceuticals, biologics, biosimilars, biotechnology, and medical devices. Our attorneys are seasoned practitioners—many of whom have technical degrees in areas key to the life sciences sector, including biology, chemistry, pharmacy, and biomedical engineering—and bring a unique understanding of the industry and perspective to our representations.
Practice Area
Our Patent Litigation Practice is one of the country’s most active and highly regarded. Our seasoned patent litigators bring extensive courtroom experience to every matter we handle. According to Lex Machina, we are among the top three national patent defense firms in the country for number of appearances and cases filed, and we also were the top national defense firm for number of patent trials in the last five years (2018–2022).
Industry
The medical device industry is currently undergoing monumental change—from supply chain challenges to disruptive technologies and economic fluctuations. To pave the way for a more accessible and innovative healthcare landscape—including advances in wearables, implants, diagnostics, mobility, drug delivery—the evolving and expansive medical device industry faces wide-ranging legal needs. Clients in this sector can tap the remarkable depth and breadth of our sector-focused and skilled attorneys in the U.S. and abroad. Our Healthcare & Life Sciences Industry Group engages clients at all points in the product development life cycle to provide sound advice and practical solutions regardless of the client’s size or the complexity of their need. We help clients navigate today’s complex regulatory landscape, defend products and reputations in the face of high-profile product liability and mass tort claims, protect innovative intellectual property (IP), and leverage cross-border experience to advise on commercial transactions.
Experience 21 results
Experience
|March 16, 2026
Winston & Strawn LLP Paris advised La Phocéenne de Cosmétique in connection with the acquisition of Laboratoires de Biarritz.
Experience
|September 23, 2025
Denali Capital Acquisition Corp Closes Business Combination with Semnur Pharmaceuticals
Winston & Strawn LLP represented Denali Capital Acquisition Corp. (OTCQB: DNQAF), a special purpose acquisition company, in the closing of its previously announced business combination with Semnur Pharmaceuticals, Inc., a clinical late-stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies and a majority-owned subsidiary of Scilex Holding Company (Nasdaq: SCLX).
Experience
|April 29, 2024
Winston represented Suntory Global Spirits (f/k/a as Beam Suntory), a world leader in spirits, in its US$1.2B sale of the Courvoisier cognac brand and related assets to Campari Group. Campari Group has assumed full ownership of Courvoisier, including properties and operations in Jarnac, France, intellectual property, maturing inventory, and case finished goods, and will distill, age, and bottle Courvoisier. The transaction will allow Suntory Global Spirits to focus its portfolio on core areas of strength as they accelerate their global growth ambitions.
Insights & News 338 results
Product Liability & Mass Torts Digest
|March 31, 2026
|2 Min Read
Court Shatters Claims Involving Exploding Sunroof
A district court in Ohio granted summary judgment to automaker Kia despite evidence that the panoramic sunroof on one of its cars “spontaneously exploded and shattered.” The court rejected the plaintiff’s claims, ruling that he failed to produce “any evidence of a design defect.”
False Claims Act Playbook
|March 23, 2026
|10+ Min Read
The annual False Claims Act (FCA) recovery statistics issued by the U.S. Department of Justice (DOJ) for Fiscal Year 2025 represent the highest single-year recovery in FCA history, underscoring that the FCA remains one of the government’s most effective tools for combating frauds involving federal funds. Winston attorneys outline expectations for FCA enforcement in 2026 and beyond based on an analysis of FY 2025 FCA activity and the priorities and goals of the current administration.
In the Media
|March 17, 2026
|1 Min Read
Andrew Hinkes Discusses SEC Crypto Enforcement Settlement With Decrypt
Winston & Strawn partner Andrew Hinkes was quoted in a Decrypt article discussing the U.S. Securities and Exchange Commission’s proposed settlement with crypto entrepreneur Justin Sun and what it may signal about the agency’s evolving approach to crypto enforcement. The SEC’s moved to settle its case against Sun for $10 million over alleged securities law violations tied to the TRX and BTT tokens. While the settlement does not require Sun to admit wrongdoing, the SEC’s ability to impose the penalty relies on the agency asserting that the relevant token transactions involved securities at the time, complicating the regulator’s narrative that most crypto tokens fall outside securities law.
Other Results 26 results
Law Glossary
Generic drugs are typically small, chemically synthesized molecules—that is, they have relatively low molecular weights, frequently less than 1000 daltons and usually between 300 and 700 daltons. Biosimilars, on the other hand, are typically substantially larger in molecular weight than small molecule drugs. For example, a monoclonal antibody—a typical biosimilar drug—generally has a molecular weight in excess of 150,000 daltons. In contrast, aspirin—a typical small molecule drug—has a molecular weight of 180 daltons.
Law Glossary
A biologic—or biologic product—is a medicine made from or by living cells, typically through a series of complex processing steps. The Public Health Service Act defines a “biological product” as “a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein (except any chemically synthesized polypeptide), or analogous product, or arsphenamine or derivative of arsphenamine (or another trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of a disease or condition of human beings.” (42 U.S.C. § 262(i).)
Law Glossary
How Does an Applicant Establish Biosimilarity?
An applicant typically demonstrates biosimilarity based on non-clinical analyses that focus on the structure and functional differences between the biosimilar and reference product.